Skip to main content
. 2021 Nov 19;4(11):e2135353. doi: 10.1001/jamanetworkopen.2021.35353

Figure 2. Demographic Profiles of Patients With Type 2 Diabetes Using Dipeptidyl Peptidase 4 (DPP4) Inhibitors and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in the Overall Study Population and the Propensity Score–Matched Population.

Figure 2.

GLP-1 indicates glucagonlike peptide-1; SMD, standardized mean difference.